| Name | Title | Contact Details |
|---|
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.
ChemoCentryx Inc is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Mountain View, CA. To find more information about ChemoCentryx Inc, please visit www.chemocentryx.com
The F. Dohmen Co. is a fifth-generation, family-owned business, which has been serving the healthcare industry for over 145 years.
Hydrogen Health is a virtual primary care solution that brings K Healths suite of digital healthcare services to employers and health plans, increasing positive long term health outcomes while substantially reducing costs.
Hyphen is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.